BioAsia 2026 positions Telangana as a global TechBio powerhouse
BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
Occlutech develops, manufactures, and commercialises medical devices for congenital heart disease, stroke prevention, and heart failure
The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research
The milestone means more than 1,000 men are now enrolled across both Phase 3 programs
HCG clinicians contributing to one of the largest bodies of oncology research from India
LIVMARLI’s new tablet form offers patients weighing 22 kg or more a convenient, one-tablet-per-dose option, complementing the existing 9.5 mg/ml oral solution
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year
Subscribe To Our Newsletter & Stay Updated